The 2023 ASCO (American Society of Clinical Oncology) annual meeting took place from June 2nd to June 6th, 2023, in Chicago, Il, USA. This year’s event was primarily an in-person event with virtual broadcasts available. The program at a glance is available here. As has been the case since 2019 we will be assessing the impact of the conference online:
From the view of HCPs:
From the view of pharma companies:
The scope of the analysis is focused on mentions coming worldwide.*
A total of 86K mentions were recorded during the listening period from May 26th, 2023, to June 20th, 2023 (one week before and two weeks after the conference).
All mentions came from Twitter.
A total of 13K unique authors were identified.
*#asco23 OR #asco2023 OR (asco NEAR/2 (2023 OR 23))
**#asco23 OR #asco2023 OR (asco NEAR/2 (2023 OR 23))
There was a slight decrease in overall mentions of 1,74% when compared to ASCO 2022, with HCPs representing the bulk of conversations at 78%. As usual, the peak of conversations happened during the conference, representing 68% of mentions recorded during the listening period.
Most liked: This tweet references the shortage of drug experienced when it comes to chemotherapies. Something originally highlighted by colleague Dr Maura Barry.
Most retweeted: This post highlights abstract 12005 which presented topical diclofenac as preventing hand-foot syndrome in pts receiving capecitabine.
Most replied to: The post receiving the most comments were congratulatory messages towards Dr. LoComte receiving the FASCO designation.
The top hashtag was
#lcsm
(lung cancer social media).
This list is in line with the most discussed diseases during the conference namely lung and breast cancers as well as
multiple myeloma.
Note: Stomach, Carcinoma of unknown primary, Head and neck cancer, Esophageal, Bile duct cancer, Skin, Thymic, Blood cancers at less than 1%
Keynote 671 was of particular interest to HCPs, showing improved event free survival as well as a reduced risk of disease recurrence, progression or death by 42% in resectable stage II, IIIA or IIIB non-small cell lung cancer.
Type of cancer mentioned:
Several results from clinical trials in RCC cancer were presented. Of note checkmate 914 reporting subgroup analyses benefiting some RCC patients. Other clinical trial mentioned include checkmate 214 and checkmate 9ER.
Type of cancer mentioned:
The main news when it comes to TAGRISSO comes from the ADAURA trial which showed improved survival in resected EGFR mutated NSCLC. Results were deemed groundbreaking, impressive and reinforcing adjuvant osimertinib as a standard of care for patients with stage IB to IIIA EGFR-mutated NSCL.
Type of cancer mentioned:
This year’s edition was heavily focused on CAR-T cell therapies and bispecific antibodies.
Highly anticipated results from the CARTITUDE-4 reflect this. Other development of note include teclistamab and talquetamab and corresponding trials RedirecTT-1 and MajesTEC-1.
Topics of discussions (type of treatment)
Volume of mentions
Most mentioned clinical trials
Most mentioned molecules
Top posts from HCPs per engagement
Activity During ASCO 2022: Top 15 commercial twitter accounts by Volume of posts (original content, excl. retweets or comments)
Comparison year to year
Find out more about Social Media Intelligence just here!